1. Immunology/Inflammation
  2. Interleukin Related
  3. LMT-28

LMT-28 

Cat. No.: HY-102084
Handling Instructions

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6–induced phosphorylation of STAT3, JAK2, and gp130.

For research use only. We do not sell to patients.

LMT-28 Chemical Structure

LMT-28 Chemical Structure

CAS No. : 1239600-18-0

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6–induced phosphorylation of STAT3, JAK2, and gp130[1].

IC50 & Target[1]

IL-6

 

In Vitro

LMT-28 reduces IL-6-induced luciferase activity by ~90% at a concentration of 50 μM and exhibits an IC50 value of 5.9 μM. LMT-28 (1-10 μM; 72 hours) inhibits IL-6-induced proliferation of the human erythroleukemic cell line TF-1[1].
LMT-28 (1-100 μM; 1 hour) selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130[1].

Cell Proliferation Assay[1]

Cell Line: TF-1 cells (1 ng/mL IL-6-induced)
Concentration: 1, 10, 100, 1000, 10000 nM
Incubation Time: 72 hours
Result: Markedly inhibited IL-6–induced TF-1 proliferation with an IC50 value of 7.5 μM.

Western Blot Analysis[1]

Cell Line: HepG2 cells (treated with 10 ng/mL IL-6)
Concentration: 1, 3, 10, 30, and 100 μM
Incubation Time: 1 hour
Result: Inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.
In Vivo

LMT-28 (0-0.5 mg/kg; p.o.; once daily for 15 days) alleviates CIA in mice[1].
LMT-28 (0.25 or 1 mg/kg; p.o.) ameliorates the progression of pancreatitis in mice. LMT-28 binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex[1].

Animal Model: Six-week-old male DBA/1J mice (collagen-induced arthritis mice, CIA)[1]
Dosage: 0-0.5 mg/kg
Administration: Oral; once daily for 15 days
Result: Markedly reduced the serum levels of cartilage oligomeric matrix protein (COMP) by 50%, serum amyloid P (SAP) by 55%, and anti-CII IgG by 62%.
Molecular Weight

311.42

Formula

C₁₇H₂₉NO₄

CAS No.

1239600-18-0

SMILES

O=C1OC[[email protected]](C(C)C)N1C([[email protected]@H](C)[[email protected]](O)C(CCCCC)=C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

LMT-28LMT28LMT 28Interleukin RelatedILIL-6subunitgp130pancreatitisnoncytotoxicityinflammationarthritisphosphorylationTNF-αInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product name:
LMT-28
Cat. No.:
HY-102084
Quantity:
MCE Japan Authorized Agent: